Our study findings support the inclusion of TMG (POT1, TERF2IP, ACD, and TERT) on genetic testing panels when a familial melanoma case exhibits spitzoid morphology in at least 25% of the tumor cells. This evidence concerns the gene ACD and neoplasm.